Polypharmacy of anxiety disorders

Polypharmacy in Psychiatry

Volumn , Issue , 2002, Pages 133-150

  Pillay, Srinivasan S ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MCLEAN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85056678486     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (24)

1. JA Ferrendelli. Relating pharmacology to clinical practice: the pharmacologic basis of rational polypharmacy. Neurology 45:S12-S16, 1995.
2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994.
3. JM Gorman, JM Kent, GM Sullivan, JD Coplan. Neuroanatomical hypothesis of panic disorder, revised. Am J Psychiatry 157:493-505, 2000.
4. FG Graeff, MC Silveira, RL Nogueira, EA Audi, RM Oliveira. Role of the amygdala and periaqueductal gray in anxiety and panic. Behav Brain Res 58:123-31, 1993.
5. DJ Newport, CB Nemeroff. Neurobiology of posttraumatic stress disorder. Curr Opin Neurobiol 10:211-218, 2000.
6. DJ Stein. Neurobiology of the obsessive-compulsive spectrum disorders. Biol Psychiatry 47:296-304, 2000.
7. RB Lydiard, O Brawman-Mintzer, JC Ballenger. Recent developments in the psychopharmacology of anxiety disorders. J Consult Clin Psychol 64:660-668, 1996.
8. EH Uhlenhuth, MB Balter, TA Ban, K Yang. International study of expert judgment on therapeutic use of benzodiazepines and other psychotherapeutic medications: IV. Therapeutic dose dependence and abuse liability of benzodiazepines in the longterm treatment of anxiety disorders. J Clin Psychopharmacol 19(suppl 2):23S-29S, 1999.
9. B Blackwell, E Marley, A Ryle. Hypertensive crisis associated with monoamine oxidase inhibitors. Lancet 15:722-723, 1964.
10. GH Manos. Possible serotonin syndrome associated with buspirone added to fluoxetine. Ann Pharmacother 34:871-874, 2000.
11. GI Hurowitz, MR Liebowitz. Antidepressant-induced rapid cycling: six case reports. J Clin Psychopharmacol 13:52-56, 1993.
12. CL Woodman, R Noyes Jr. Panic disorder: treatment with valproate. J Clin Psychiatry 55:134-136, 1994.
13. AC Pande, MH Pollack, J Crockatt, M Greiner, G Chouinard, RB Lydiard, CB Taylor, SR Dager, T Shiovitz. Placebo-controlled study of gabapentin treatment of panic disorder. J Clin Psychopharmacol 20:467-471, 2000.
14. J Pettiford. Other clinical uses of olanzapine. Aust NZ J Psychiatry 34:532-533, 2000.
15. LK Michelson, K Marchione. Behavioral, cognitive, and pharmacological treatments of panic disorder with agoraphobia: critique and synthesis. J Consult Clin Psychol59:100-114, 1991.
16. SA Stephen. Cardiac failure with propranolol. Br Med J 2:428, 1968.
17. J Froom, J Trilling. Reducing antihypertensive medication use in nursing home patients. Arch Fam Med 9:378-383, 2000.
18. JM Gorman. Comorbid depression and anxiety spectrum disorders. Depress Anxiety 4:160-168, 1996-97.
19. SL Rauch, CR Savage, NM Alpert, AJ Fischman, MA Jenike. The functional neuro anatomy of anxiety: a study of three disorders using positron emission tomography and symptom provocation. Biol Psychiatry 42:446-452, 1997.
20. PL Delgado, FA Moreno. Role of norepinephrine in depression. J Clin Psychiatry61(suppl 1):5-12, 2000.
21. MJ Garvey. Panic disorder: guidelines to safe use of benzodiazepines. Geriatrics 48: 49-53, 56-58, 1993.
22. PM Salkovskis, DM Clark, MG Gelder. Cognition-behaviour links in the persistence of panic. Behav Res Ther 34:453-458, 1996.
23. H Orenstein, A Peskind, MA Raskind. Thyroid disorders in female psychiatric patients with panic disorder or agoraphobia. Am J Psychiatry 145:1428-1430, 1988.
24. G Bovasso, W Eaton. Types of panic attacks and their association with psychiatric disorder and physical illness. Compr Psychiatry 40:469-477, 1999.